Sacramento Bee Logo

Viewpoints: An unprecedented collaboration in the fight against cancer | The Sacramento Bee

×
  • E-edition
    • Customer Service
    • SacBee Rewards
    • About Us
    • About Us
    • Contact Us
    • Apps
    • Mobile & Apps
    • Twitter, Facebook, Google+, YouTube
    • News in Education (NIE)
  • Newsletters

    • Sacramento Region
    • Arena
    • City Beat
    • Crime
    • Local Govt Salary Database
    • The Homeless
    • Marcos Bretón
    • Transportation
    • Education
    • Environment
    • Health & Medicine
    • Traffic Conditions
    • Weather
    • Communities
    • Elk Grove
    • Folsom/El Dorado
    • Roseville/Placer
    • Yolo
    • Sports
    • Kings
    • NBA News
    • 49ers
    • Giants
    • Oakland A's
    • High School Sports
    • Joe Davidson
    • More Sports
    • Raiders
    • NFL News
    • MLB News
    • River Cats
    • Soccer
    • Colleges
    • Golf
    • Autos Racing
    • Politics
    • Capitol Alert
    • State Workers
    • The California Influencer Series
    • Local Elections
    • PoliGRAPH
    • State Worker Salary Database
    • Legislative Gifts
    • Local Elections
    • California Elections
    • Election Endorsements
    • Election 2018
    • Voter Guide
    • Investigations
    • Data Tracker
    • Public Eye
    • Afghan Refugees
    • Nursing Homes
    • Opinion
    • Editorials
    • Election Endorsements
    • Viewpoints
    • Influencers Opinion
    • California Forum
    • Letters to the Editor
    • Submit a Letter
    • Jack Ohman
    • Editorial Board
    • Entertainment & Life
    • Arts & Theater
    • Books
    • Home & Garden
    • Movies
    • Music
    • Outdoors
    • Pets
    • Travel
    • More Entertainment
    • Events Calendar
    • Horoscopes
    • Comics
    • Puzzles
    • TV Listings
    • Sacbee Rewards
    • Food & Drink
    • Restaurants News & Reviews
    • Restaurant Directory
    • Cooking & Recipes
    • Beer
    • Wine
    • Appetizers Blog
    • California
    • Big Valley
    • Marijuana
    • Wildfires
    • Water & Drought
    • Lottery
    • Business
    • Real Estate
    • Market Summary
    • Cathie Anderson
    • Nation & World
    • National
    • World
    • Technology
    • Family
    • Celebrities
    • TV news
    • Weird News
    • Video Break
    • News Obituaries
    • Death Notices
    • FAQ
    • ObitMessenger
    • In Memoriam

    • The Sacramento Bee Store
    • Golf Card
    • Farm to Fork Dining Card
  • Jobs
  • Moonlighting
  • Cars
  • Homes
  • Classifieds
  • Legal Notices
  • Place an Ad
  • Advertise
  • Mobile & Apps

Viewpoints

Viewpoints: An unprecedented collaboration in the fight against cancer

By David Gandara - Special to The Bee

    ORDER REPRINT →

June 29, 2014 12:00 AM

When I began as an oncologist in the late 1970s, hormone therapies were revolutionizing breast cancer treatment. But as I witnessed in my early career caring for military veterans, the outlook for lung cancer was dismal. I saw it as an opportunity to make a difference.

Today, lung cancer remains the No. 1 cancer killer of men and women. It is a disease that will affect nearly 225,000 people in the U.S. this year and kill more than 159,000, accounting for about 27 percent of all cancer deaths.

The fight against this most complex of cancers has made some progress, however. We better understand the genetic characteristics of individual tumors, and we have been able to develop and test drugs specifically targeted to some of those tumors, extending and improving the quality of our patients’ lives. At the UC Davis Comprehensive Cancer Center, for example, I have late-stage lung cancer patients who are working, exercising, traveling and spending precious time with their families because we were able to match their tumor to a drug designed for their particular molecular profile.

Unfortunately, because of an outdated, inefficient and costly process of drug development, clinical trial recruitment and drug approval, new, more effective therapies are often too few and too late. We need a new approach, one that streamlines the process and exploits the tremendous advances made in genomics and DNA sequencing technologies that can reveal the genetic variations and mutations that spur tumor growth.

Sign Up and Save

Get six months of free digital access to The Sacramento Bee

SUBSCRIBE WITH GOOGLE

#ReadLocal

This month, federal health agencies, pharmaceutical companies, advocacy groups and cancer specialists around the country embarked on a collaboration, with the launch of a multicenter, multidrug clinical trial matching lung cancer patients with promising new treatments based on each patient’s unique tumor profile.

The approach we have taken is unprecedented in the history of cancer clinical trials. Its aim is to find effective treatments faster by giving more patients access to experimental therapies, optimizing the clinical trial infrastructure and reducing recruitment hurdles for patients and their doctors.

Called the Lung Cancer Master Protocol, or Lung-MAP, the trial will simultaneously test five experimental drugs, including four molecularly targeted drugs and an immunotherapy drug for squamous cell lung cancer. Approximately 1,200 patients will be screened per year, and each will be assigned to the trial arm best matched to their tumor’s genomic profile.

The protocol is a major departure from the traditional clinical trial model. In a typical trial for a targeted therapy, patients undergo multiple single-gene diagnostic tests to determine if they are eligible for one of many different studies. This trial will use just a single test for more than 200 cancer-related genes for genomic alterations. We estimate that based on the results of the test, 60 percent of patients will be eligible for one of four investigational, targeted drugs being tested in the trial. The rest will go into a trial of a fifth drug, an immunotherapy.

We anticipate that many more patients will be able to access promising new drugs because more than 500 medical centers across the U.S. will offer the trial, and because all the clinical investigators will share information and infrastructure. Unlike typical trials of targeted drugs, often hampered by low patient accrual rates, this trial will draw a majority of eligible patients, making collection of clinical data easier and faster. That should translate into quicker approval of effective new therapies for patients who need them now.

Even if some arms of the trial don’t succeed, the information we get can fuel research into other promising therapies.

Like any new approach, the master protocol system will face its challenges. But we are prepared for them. We’ve already overcome the greatest challenge: getting often disparate interests, even competitors, to work together in an unprecedented way on a common problem. Never before have the Food and Drug Administration, SWOG (the nation’s leading cancer clinical trials cooperative group), National Cancer Institute, Foundation for the National Institutes of Health, and five pharmaceutical companies and private advocacy organizations collaborated like this to tackle any kind of cancer. If the approach is successful, the cost to develop new drugs will be just one-tenth of what a pharmaceutical company would normally spend on its own.

The long-term goal is for the protocol to be self-sustaining. As arms of the study close after meeting their research goals, we can open new arms to test new therapies. If the approach works for lung cancer, it could be a model for addressing additional cancers and other complex diseases. Lung cancer patients – and anyone facing a life-threatening illness – deserve no less.

  Comments  

Videos

Painting the Delta

Homeless in Sacramento

View More Video

Trending Stories

Will ‘basic income’ become the California norm? Stockton starts $500 no-strings payments

February 15, 2019 03:30 AM

Gavin Newsom says California plans to sue Donald Trump over national emergency declaration

February 15, 2019 10:32 AM

El Niño officially arrives: Rising rivers bring flood warnings to Sacramento, Yolo

February 14, 2019 12:21 PM

Interstate 80 closed in both directions amid whiteout conditions and collisions

February 14, 2019 07:44 PM

Does this school trip cross line between church and state? Some Sacramento parents say yes

February 14, 2019 03:30 AM

Read Next

Lots of luck to Amy Klobuchar. History shows she’ll need it

California Forum

Lots of luck to Amy Klobuchar. History shows she’ll need it

By Jack Ohman

    ORDER REPRINT →

February 16, 2019 12:01 AM

Minnesota presidential candidates always look good on paper, but so many have failed. Sen. Amy Klobuchar, in the midst of a snowstorm, threw her hat into the ring. She’ll need a lot of luck to win.

KEEP READING

Sign Up and Save

#ReadLocal

Get six months of free digital access to The Sacramento Bee

SUBSCRIBE WITH GOOGLE

MORE VIEWPOINTS

One year after Parkland shooting, gun violence remains a threat

Viewpoints

One year after Parkland shooting, gun violence remains a threat

February 14, 2019 12:01 AM
Glowing coverage of Kamala Harris ignores reality

Bill Whalen

Glowing coverage of Kamala Harris ignores reality

February 12, 2019 12:01 AM
Californians deserve safe drinking water. It’s time for the Legislature to deliver it

Viewpoints

Californians deserve safe drinking water. It’s time for the Legislature to deliver it

February 12, 2019 12:01 AM
Prosecutors’ attack on youth justice reform undermines democracy

California Forum

Prosecutors’ attack on youth justice reform undermines democracy

February 10, 2019 12:01 AM
Commentary: School districts set poor example for students

California Forum

Commentary: School districts set poor example for students

February 10, 2019 03:01 AM
It’s too late to save my son’s life, but this drug can save others

California Forum

It’s too late to save my son’s life, but this drug can save others

February 10, 2019 12:01 AM
Take Us With You

Real-time updates and all local stories you want right in the palm of your hand.

Icon for mobile apps

The Sacramento Bee App

View Newsletters

Subscriptions
  • Start a Subscription
  • Customer Service
  • eEdition
  • Vacation Hold
  • Pay Your Bill
  • Rewards
Learn More
  • About Us
  • Contact Us
  • Newsletters
  • News in Education
  • Photo Store
Advertising
  • Place a Classified Ad
  • Place a Legal Notice
  • Place a Digital Ad
  • Place a Newspaper Ad
Copyright
Commenting Policy
Corrections Policy
Privacy Policy
Terms of Service


Back to Story